IASO Bio, a biopharmaceutical company with operations in Shanghai, Nanjing, and California, presented preliminary Phase I data for RD140, a fully human BCMA/GPRC5D dual-targeted CAR-T therapy, at the 2026 International Myeloma Society Annual Meeting, reporting an objective response rate of 88.9% across nine heavily pretreated patients with relapsed/refractory multiple myeloma or plasma cell leukemia.
The investigator-initiated NCT06655519 study enrolled patients with relapsed/refractory multiple myeloma after at least three prior lines of therapy, as well as patients with plasma cell leukemia following progression after first-line treatment. All nine infused patients were triple-class exposed, six were penta-exposed, and two had previously received BCMA-targeted therapy.
As of the May 6, 2026 data cutoff, median follow-up was 6.05 months. The six patients treated at 3×10⁵ cells/kg achieved a 100% objective response rate, while 88.9% of all patients achieved minimal residual disease negativity at the 10⁻⁵ threshold. Median progression-free survival had not been reached.
RD140 simultaneously targets BCMA and GPRC5D and is manufactured using IASO Bio's FasT CAR-T platform, which the company said can complete cell production in three to four days.